Alpha 2.0
Login Register
» Authors » Jintanat Ananworanich

Jintanat Ananworanich

Explore the profile of Jintanat Ananworanich including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 358
Citations 6543
Followers 0
Related Specialties
Infectious Diseases
Microbiology
General Medicine
Top 10 Co-Authors
Nittaya Phanuphak
Praphan Phanuphak
Suteeraporn Pinyakorn
Eugene Kroon
Kiat Ruxrungtham
Merlin L Robb
Thanyawee Puthanakit
Torsak Bunupuradah
Victor Valcour
Stephen J Kerr
Published In
AIDS
J Acquir Immune Defic Syndr
J Virus Erad
Clin Infect Dis
Antivir Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Activation of CXCR3 Tfh cells and B cells in lymph nodes during acute HIV-1 infection correlates with HIV-specific antibody development
Mitchell J, Buranapraditkun S, Gantner P, Takata H, Dietze K, Nguessan K, et al.
J Virol . 2025 Feb; :e0153224. PMID: 39932316
Importance: Early initiation of antiretroviral therapy (ART) is important to limit the seeding of the long-lasting HIV-1 reservoir; however, it also precludes the development of HIV-specific antibodies that can help...
2.
Impaired creatinine-based estimated glomerular filtration rate in Thai individuals switching to dolutegravir: illustrating the role of cystatin C testing to aid clinical decision making
Sacdalan C, Austin C, Varma A, Pinyakorn S, Kroon E, Colby D, et al.
AIDS Res Ther . 2025 Feb; 22(1):15. PMID: 39920714
Introduction: Data about impact of switch to dolutegravir (DTG)-based antiretroviral therapy (ART) on estimated glomerular filtration rate (eGFR) in Asians are scarce. RV254/SEARCH010 is a prospective observational cohort in Bangkok,...
3.
A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults
Soens M, Ananworanich J, Hicks B, Lucas K, Cardona J, Sher L, et al.
Vaccine . 2025 Feb; 50:126847. PMID: 39919447
Background: Messenger RNA (mRNA)-based influenza vaccines have the potential to improve upon limitations of current vaccine approaches to seasonal influenza. Methods: Here we report findings on the primary and secondary...
4.
RSM01, a novel respiratory syncytial virus monoclonal antibody: preclinical characterization and results of a first-in-human, randomised clinical trial
Bonavia A, Levi M, Rouha H, Badarau A, Terstappen J, Watson S, et al.
BMC Infect Dis . 2024 Dec; 24(1):1378. PMID: 39627701
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease among infants and young children worldwide, especially in low- and middle-income countries (LMICs). RSM01 is a...
5.
Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50-75 years: a phase 1/2, open-label, randomised trial
Hsu D, Jayaraman A, Pucci A, Joshi R, Mancini K, Chen H, et al.
Lancet Infect Dis . 2024 Sep; 25(1):25-35. PMID: 39245055
Background: Inclusion of additional influenza A/H3N2 strains in seasonal influenza vaccines could expand coverage against multiple, antigenically distinct, cocirculating A/H3N2 clades and potentially replace the no longer circulating B/Yamagata strain....
6.
Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial
Ananworanich J, Lee I, Ensz D, Carmona L, Schaefers K, Avanesov A, et al.
J Infect Dis . 2024 Jun; 231(1):e113-e122. PMID: 38934845
Background: Seasonal influenza remains a global public health concern. A messenger RNA (mRNA)-based quadrivalent seasonal influenza vaccine, mRNA-1010, was investigated in a first-in-human, phase 1/2 clinical trial conducted in 3...
7.
Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption
Mdluli T, Slike B, Curtis D, Shubin Z, Tran U, Li Y, et al.
Cell Rep . 2024 Jun; 43(6):114344. PMID: 38850529
A heterologous Ad26/MVA vaccine was given prior to an analytic treatment interruption (ATI) in people living with HIV-1 (mainly CRF01_AE) who initiated antiretroviral treatment (ART) during acute HIV-1. We investigate...
8.
Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines
Russell C, Fouchier R, Ghaswalla P, Park Y, Vicic N, Ananworanich J, et al.
Hum Vaccin Immunother . 2024 Apr; 20(1):2336357. PMID: 38619079
Influenza remains a public health threat, partly due to suboptimal effectiveness of vaccines. One factor impacting vaccine effectiveness is strain mismatch, occurring when vaccines no longer match circulating strains due...
9.
Adaptive NK Cells Rapidly Expand during Acute HIV Infection and Persist Despite Early Initiation of Antiretroviral Therapy
Hearps A, Zhou J, Agius P, Ha P, Lee S, Price P, et al.
J Immunol . 2024 Apr; 212(10):1553-1563. PMID: 38558245
HIV is associated with NK cell dysfunction and expansion of adaptive-like NK cells that persist despite antiretroviral therapy (ART). We investigated the timing of NK cell perturbations during acute HIV...
10.
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial
Crowell T, Ritz J, Zheng L, Naqvi A, Cyktor J, Puleo J, et al.
AIDS . 2024 Mar; 38(8):1141-1152. PMID: 38489580
Objective: To assess how antiretroviral therapy (ART) initiation during acute or early HIV infection (AEHI) affects the viral reservoir and host immune responses. Design: Single-arm trial of ART initiation during...